Zelda Therapeutics has engaged international experts to advise it on three experimental clinical trials it kicked off in humans over the past two years.
The medicinal cannabis drug developer (ASX:ZLD) launched clinical trials in patients with insomnia and opioid dependence last year, and undertook an observational study in Chilean children with autism in 2017.
It has now tapped the International Cannabis and Cannabinoids Institute (ICCI) to support those clinical trial programmes.
The opioid dependence trial must first pass Human Research Ethics Committee guidelines, with Zelda saying submissions to the HREC will take place this quarter. Several patients have reportedly completed the insomnia trial “with no reports of significant adverse events”, while about a third of patients have been enrolled in the observational autism study taking place in the US.
Shares in Zelda rose 5 per cent to 6.1c on the news.